Sun Pharma is the biggest loser on the Nifty as it missed estimates. Also, the management gave a very conservative guidance of 8-10 percent growth in consolidated sales for FY17. A bullish SP Tulsian of sptulsian.com gave a support price of Rs 700.
first published: May 31, 2016 03:47 pm
A collection of the most-viewed Moneycontrol videos.
Why This Tenant Says Bandra Is Better Than California | The Tenant
Nifty Clocks Triple-Digit Gains After RBI Rate Cut But Logs Losses For The Week| Closing Bell Live
LIVE: RBI Governor Sanjay Malhotra Delivers Key Monetary Policy Statement | Interest Rates & Outlook
Nifty’s Move Hinges On RBI Rate Decision; HUL, ITC Hotels In Focus| Opening Bell Live
